Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Voluntary Disclosure of the Inclusion of ZG006 for Injection for the Treatment of Advanced Neuroendocrine Carcinoma in the Publicity List for Breakthrough Therapy Designation

· Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Inclusion of ZG006 for Injection for the Treatment of Advanced Neuroendocrine Carcinoma in the Publicity List for Breakthrough Therapy Designation

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis